LiDCO Group plc provided revenue guidance for the six months ended July 31, 2012. The Board expects that these results will show revenue for the period to have increased by approximately 4% to £3.3 million with cash at the period end of approximately £1.0 million. Product sales (excluding non recurring license fees) were up by approximately £500,000, an increase of 18%.

The Board also announced John Barry has resigned as Sales and Marketing Director with immediate effect. John has been with LiDCO for 11 years; he has helped the company establish its technology in the critical care and high-risk surgery arenas and seen LiDCO breakthrough to profitability last year. John is moving on to take up an new opportunity with an emerging technology.